Maze Therapeutics, Inc (MAZE)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Maze Therapeutics, Inc (MAZE) is down 38.3% since the beginning of the year. At $26 per share, MAZE is trading 52.3% below its 52-week high of $54.

Maze Therapeutics, Inc (MAZE) has returned -38.28% so far this year and 128.71% over the past 12 months.

Based on dividend-adjusted daily data since Jan 31, 2025, MAZE's average daily return is +0.30%, while the average monthly return is +4.99%. At this rate, an investment would double in approximately 1.2 years.

Historically, 50% of months were positive and 50% were negative. The best month was Sep 2025 with a return of +79.0%, while the worst month was Mar 2026 at -34.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.

On a daily basis, MAZE closed higher 50% of trading days. The best single day was Sep 11, 2025 with a return of +54.8%, while the worst single day was Mar 25, 2026 at -35.2%.

Maze Therapeutics, Inc has an annualized alpha of 83.53%, beta of 0.90, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since January 31, 2025.

• This stock captured 711.00% of S&P 500 Index gains and 338.64% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

MAZE ranks 81 for risk / return — in the top 81% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Maze Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Maze Therapeutics, Inc was 54.51%, occurring on Jun 8, 2026. The portfolio has not yet recovered.

The current Maze Therapeutics, Inc drawdown is 50.67%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Maze Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Maze Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.